VetrixBio’s VTX-304 Shows Promise for Canine Osteoarthritis
RALEIGH, North Carolina, June 5, 2026 VetrixBio has announced encouraging first clinical data for VTX-304, its investigational first-in-class bispecific...
AI drug discovery artificial intelligence Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
RALEIGH, North Carolina, June 5, 2026 VetrixBio has announced encouraging first clinical data for VTX-304, its investigational first-in-class bispecific...
CLEVELAND, Ohio and HOUSTON, Texas, June 5, 2026 Neuronoff has achieved a major clinical milestone with the successful implantation...
WHITE PLAINS, New York, June 5, 2026 Retia Medical has announced a significant expansion of its commercial partnership with...
